hackint0sh/New-Dataset huggingface dataset:
Researchers will compare those in the mindfulness course with those receiving standard care in preparation for a larger future study to see how mindfulness impacts stress and inflammation in individuals with RA. conditions: Arthritis, Rheumatoid studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL interventionModelDescription: Participants will be randomly assigned to participate in a mindfulness-based stress reduction (MBSR) course or treatment as usual (TAU). Randomization will be done using a program-tracking system. primaryPurpose: OTHER masking: DOUBLE maskingDescription: Physicians completing joint exams to assess clinical disease activity, including the principal investigator, will be blinded to participant assignment. It will not be possible for participants to be blinded to treatment condition. whoMasked: INVESTIGATOR whoMasked: OUTCOMES_ASSESSOR count: 40 type: ESTIMATED name: Mindfulness Program measure: Patient Satisfaction as Assessed by CSQ-8, Adapted for DREAMER Study measure: MBSR Course Attendance (Intervention Adherence) measure: Percent of Study Completers (Study Retention) measure: Clinical Disease Activity Index (CDAI) measure: Disease Activity Score in 28 Joints (DAS-28) measure: Modified Rheumatoid Arthritis Disease Activity Index, 5-item (RADAI-5) measure: Patient-Reported Outcomes Measurement Information System (PROMIS) Pain Interference, 4-Item Scale measure: Patient-Reported Outcomes Measurement Information System (PROMIS) Fatigue, 4-Item Scale measure: Patient-Reported Outcomes Measurement Information System (PROMIS) Global Mindfulness, 13-item Scale measure: Perceived Stress Scale, 10-item measure: Brief Resilience Scale sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Osher Center for Integrative Health status: RECRUITING city: San Francisco state: California zip: 94115 country: United States lat: 37.77493 lon: -122.41942 hasResults: False
nctId: NCT06276374 id: SMC 2023-12-107 briefTitle: Highest Efficacy of Dual Antiplatelet Therapy After Carotid Artery Stenting in High Bleeding Risk Patients overallStatus: NOT_YET_RECRUITING date: 2024-03-01 date: 2026-11-30 date: 2027-12-31 date: 2024-02-26 date: 2024-02-26 name: Woo-Keun Seo class: OTHER briefSummary: To compare the safety of dual antiplatelet therapy with aspirin and clopidogrel and single antiplatelet therapy administered from 30 days to 12 months following carotid artery stenting on clinically significant bleeding and its prevention effects on net clinical events including combined cardiovascular and cerebrovascular accidents and major bleeding events in patients with carotid artery disease who are at high bleeding risk. conditions: Carotid Artery Diseases studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: NONE count: 1556 type: ESTIMATED name: Patients who are scheduled to undergo carotid artery stenting measure: Clinically significant bleeding measure: Combined cardiovascular and cerebrovascular accidents sex: ALL minimumAge: 19 Years stdAges: ADULT stdAges: OLDER_ADULT hasResults: False
nctId: NCT06276361 id: ROV-QUAR-2023-01 briefTitle: Pharmacokinetics, Safety and Tolerability of Different Formulations and Dose Strengths of Quarterly Risperidone (QUAR) in Patients With Schizophrenia acronym: QUARTZ overallStatus: RECRUITING date: 2023-09-26 date: 2026-05 date: 2026-05 date: 2024-02-26 date: 2024-03-12 name: Rovi Pharmaceuticals Laboratories class: INDUSTRY briefSummary: This is a single ascending dose phase 1 study to evaluate the pharmacokinetics (PK), safety, and tolerability of a single intramuscular (IM) injection of quarterly Risperidone (QUAR) for different formulations and dose strengths in participants with schizophrenia. conditions: Schizophrenia studyType: INTERVENTIONAL phases: PHASE1 allocation: RANDOMIZED interventionModel: SEQUENTIAL primaryPurpose: TREATMENT masking: NONE count: 100 type: ESTIMATED name: Oral risperidone; QUAR F1/2, Dose 1 - Gluteal name: Oral risperidone; QUAR F1/2, Dose 2 - Gluteal name: Oral risperidone; QUAR F1/2, Dose 3 - Gluteal name: Oral risperidone; QUAR F1/2, Dose 3 - Deltoids measure: λz measure: t1/2 measure: Tmax measure: Cmax measure: Cmin measure: Clast measure: AUC0-t measure: AUCinf measure: AUCextrap measure: Vd/F measure: Cl/F sex: ALL minimumAge: 18 Years maximumAge: 65 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Investigational Site status: RECRUITING city: Amman country: Jordan lat: 31.95522 lon: 35.94503 hasResults: False
nctId: NCT06276348 id: 20226892 briefTitle: Newborn Genomic Sequencing Pilot Study overallStatus: ACTIVE_NOT_RECRUITING date: 2023-03-13 date: 2024-02-28 date: 2024-09 date: 2024-02-26 date: 2024-03-04 name: Rady Pediatric Genomics & Systems Medicine Institute class: OTHER briefSummary: The goal of this clinical trial is to test a new method for newborn screening using whole genome sequencing, called BeginNGS. Newborns who are not suspected of having genetic diseases and who are admitted to the NICU at Rady Children's Hospital, San Diego, will be enrolled. The main questions this study aims to answer are:
* WES conditions: Genetic Disease studyType: INTERVENTIONAL phases: NA allocation: NA interventionModel: SINGLE_GROUP interventionModelDescription: Single group, multiple interventions. All enrollees receive all interventions. primaryPurpose: SCREENING masking: NONE count: 120 type: ACTUAL name: Whole genome sequencing name: BeginNGS test name: WES measure: Proportion of enrolled infants who are diagnosed with a genetic disease by DWGS. measure: Proportion of enrolled infants who are identified with a genetic disease by BeginNGS. measure: Proportion of enrolled infants who are identified with a genetic disease by WES. measure: Proportion of enrolled infants who have a positive standard NBS test. measure: Proportion of parents approached who agree to participate in the study. measure: Parental reasons for refusal. measure: Time from sample arriving in lab to return of DWGS results. measure: Time from birth to return of DWGS results. measure: Results of confirmatory testing if BeginNGS or WES identifies a diagnostic finding not reported by DWGS. sex: ALL minimumAge: 1 Day maximumAge: 10 Days stdAges: CHILD facility: Rady Children's Hospital San Diego city: San Diego state: California zip: 92123 country: United States lat: 32.71533 lon: -117.15726 hasResults: False
nctId: NCT06276335 id: IRAS:322440 briefTitle: Influence of Timing of Implant Placement on Early Healing Molecular Events overallStatus: NOT_YET_RECRUITING date: 2024-05-01 date: 2026-04-30 date: 2026-05-30 date: 2024-02-23 date: 2024-03-08 name: Queen Mary University of London class: OTHER name: University of Zurich briefSummary: Dental implants have been on the market for several years and they are routinely used to replace single/multiple missing teeth with a high success rate. However, there is still a limited number of studies comparing the influence of timing of implant placement on wound healing. In addition, there is no data available on the signaling pathways and the expression of healing biomarkers involved in the early stages of osseointegration after immediate implant placement (IP) or delayed implant placement (DP).
The primary objective of this study is to describe changes in the expression of inflammatory, angiogenesis and osseous biomarkers of saliva at 1, 3, 7, 15 and 30 days and of PICF at 3, 7, 15 and 30 days after immediate implant placement (IP) compared with delayed placement (DP). conditions: Dental Implant conditions: Healing Wound conditions: Biomarkers conditions: Saliva studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: OTHER masking: SINGLE whoMasked: OUTCOMES_ASSESSOR count: 24 type: ESTIMATED name: Immediate implant placement and guided bone regeneration (Test) name: Late implant placement and guided bone regeneration (Control) measure: Changes in the expression of inflammatory, angiogenesis and osseous biomarkers of PICF and saliva measure: Blood flow changes measure: Soft tissue volume changes measure: Peri-implant bone level measure: Full mouth plaque score (FMPS) measure: Full mouth bleeding score (FMBS) measure: Probing pocket depth (PPD) measure: Gingival recession (REC) measure: Clinical attachment level (CAL) measure: Suppuration measure: Patient satisfaction at 6 months after loading measure: Changes in the pink esthetic score (PES) measure: Changes in the white esthetic score (WES) measure: Changes in the papilla fill index (PFI) measure: Implant survival sex: ALL minimumAge: 25 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Centre for Oral Clinical Research city: London zip: E1 2AD country: United Kingdom name: Nikolaos Donos, DDS MS PhD role: CONTACT phone: +44(0)2078823063 email: BHNT.Clinicaloralresearchcentre@nhs.net name: Vandana Luthra, Dr role: CONTACT phone: +44(0)2078826348 email: BHNT.Clinicaloralresearchcentre@nhs.net name: Nikolaos Donos, DDS MS PhD role: PRINCIPAL_INVESTIGATOR lat: 51.50853 lon: -0.12574 hasResults: False
nctId: NCT06276322 id: HU-FTR-SZK-01 briefTitle: Assessment of All Spine Segments ın Individuals With Low Back Pain overallStatus: RECRUITING date: 2023-12-01 date: 2024-03-20 date: 2024-12-31 date: 2024-02-23 date: 2024-03-07 name: Hacettepe University class: OTHER briefSummary: The aim of the study is to evaluate the kinematics of all spine segments in 3 planes and compare them with asymptomatic controls using wearable technology while performing functional tasks that patients with chronic low back pain often describe as painful in their daily lives. conditions: Low Back Pain studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL interventionModelDescription: Low back pain group and healthy group primaryPurpose: OTHER masking: NONE count: 46 type: ESTIMATED name: Low back pain group name: Healthy group measure: Evaluation of the kinematics of the all spine during walking measure: Evaluation of the kinematics of the all spine during Bending Forward and Lifting Objects measure: Evaluation of the kinematics of the all spine during Standing from Sitting measure: Evaluation of the kinematics of the all spine during Climbing Step measure: Spine Normal Joint Movement evaluation measure: Pain intensity: Visual Analog Scale measure: Oswestry Disability Index measure: Fear of movement: Tampa Kinesiophobia Scale sex: ALL minimumAge: 18 Years maximumAge: 55 Years stdAges: ADULT facility: Hacettepe university status: RECRUITING city: Ankara state: Altındağ zip: 06050 country: Turkey name: Sümeyye Zehra Güler, MSc role: CONTACT phone: 5079320390 phoneExt: +90 email: zhrkzlk1906@gmail.com lat: 39.91987 lon: 32.85427 hasResults: False
nctId: NCT06276309 id: NECC2401 briefTitle: Protein Molecular Characteristics and Prognosis of Cervical Neuroendocrine Tumors overallStatus: RECRUITING date: 2024-02-01 date: 2024-06-30 date: 2024-06-30 date: 2024-02-23 date: 2024-02-23 name: Fujian Maternity and Child Health Hospital class: OTHER briefSummary: The clinical diagnosis and treatment data of 300 cases of cervical neuroendocrine tumors were collected, including age, preoperative biopsy pathology results, postoperative histopathological results, TCT results, and colposcopy biopsy pathology results. At the same time, paraffin tissue specimens (remaining specimens after pathological diagnosis) from 100 cases of cervical neuroendocrine tumors from multiple centers across the country were collected to establish a cervical neuroendocrine tumor data follow-up database. Protein concentration and omics analysis were performed on the data results, to evaluate the molecular characteristics and prognosis of cervical neuroendocrine tumor proteins, and to preliminarily explore its clinical application value. conditions: Neuroendocrine Neoplasm conditions: China conditions: Women conditions: Cervical Cancer conditions: Cervical Lesion studyType: OBSERVATIONAL observationalModel: COHORT timePerspective: RETROSPECTIVE count: 300 type: ESTIMATED measure: mortality rate measure: Disease-free survival sex: FEMALE stdAges: CHILD stdAges: ADULT stdAges: OLDER_ADULT facility: Fujian Maternity and Child Health Hospital status: RECRUITING city: Fuzhou state: Fujian zip: 350001 country: China name: Binhua Dong role: CONTACT phone: +8687558732 email: dbh18-jy@126.com lat: 26.06139 lon: 119.30611 facility: Fujian Provincial Hospital status: RECRUITING city: Fuzhou state: Fujian country: China name: Dongjie Chen role: CONTACT lat: 26.06139 lon: 119.30611 facility: Ningde Mindong Hospital status: RECRUITING city: Ningde state: Fujian country: China name: Fang Xie role: CONTACT lat: 26.66167 lon: 119.52278 facility: Putian City first Hospital status: RECRUITING city: Putian state: Fujian country: China name: Yi Chen role: CONTACT lat: 25.43944 lon: 119.01028 facility: The Second Affiliated Hospital of Fujian Medical University status: RECRUITING city: Quanzhou state: Fujian country: China name: Luhong Li role: CONTACT lat: 24.91389 lon: 118.58583 facility: Zhangzhou affiliated Hospital of Fujian Medical University status: RECRUITING city: Zhangzhou state: Fujian zip: 363000 country: China name: Feifeng Shi, M.D role: CONTACT lat: 24.51333 lon: 117.65556 facility: Maternal and Child Health Hospital of Hubei Province status: RECRUITING city: Wuhan state: Hubei country: China name: Hongning Cai, M.D role: CONTACT phone: +8615926224867 lat: 30.58333 lon: 114.26667 facility: Xiangya Hospital, Central South University status: RECRUITING city: Changsha state: Hunan country: China name: Yu Zhang role: CONTACT lat: 28.19874 lon: 112.97087 facility: Jiangxi maternal and Child Health Hospital status: RECRUITING city: Nanchang state: Jiangxi country: China name: Ling Li role: CONTACT lat: 28.68396 lon: 115.85306 hasResults: False
nctId: NCT06276296 id: 0001 briefTitle: Heart Rate Variability After Ablation overallStatus: RECRUITING date: 2023-03-01 date: 2024-08-31 date: 2024-10-01 date: 2024-02-23 date: 2024-02-23 name: Charles University, Czech Republic class: OTHER name: Vascular surgery, University hospital Královské Vinohrady, Prague briefSummary: Pulsed-field catheter ablation is a promising new treatment method for patients with atrial fibrillation. The mechanism of cell damage here is different from that of classic catheter ablation, in which the ganglion plexuses around the pulmonary veins are also damaged and thus changes in the autonomic nervous system occur. The aim of the work is to find out, using heart rate variability, whether the autonomic system is less affected during pulsed field ablation than in classic radiofrequency ablation. conditions: Atrial Fibrillation studyType: OBSERVATIONAL observationalModel: CASE_CONTROL timePerspective: PROSPECTIVE count: 60 type: ESTIMATED name: Holter EKG - 1 day before ablation name: Radiofrequency ablation name: Pulsed field ablation name: Holter EKG - 1 month after ablation measure: Mean RR interval (ms) measure: SDNN (ms) measure: RMSSD (ms) measure: pNN50 (%) measure: peak frequency (Hz) measure: power (ms2) measure: LF/HF ratio measure: SD1 (ms) measure: SD2 (ms) measure: SD2/SD1 measure: ApEn measure: Correlation dimension sex: ALL minimumAge: 18 Years maximumAge: 75 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Cardiocenter, 3rd Medical School, Charles University and University Hospital Kralovske Vinohrady status: RECRUITING city: Prague zip: 10034 country: Czechia name: Jana Vesela, Ing.,Ph.D. role: CONTACT phone: +420267162714 email: janca.zd@gmail.com name: Pavel Osmancik, MD,Ph.D. role: CONTACT phone: +420267162714 email: pavel.osmancik@fmail.com lat: 50.08804 lon: 14.42076 hasResults: False
nctId: NCT06276283 id: DZ2022E0006 briefTitle: DZD9008 In Combination With Bevacizumab in Locally Advanced or Metastatic NSCLC Patients With EGFR Mutation (WU-KONG29) overallStatus: RECRUITING date: 2023-02-15 date: 2025-05-31 date: 2026-02-28 date: 2024-02-23 date: 2024-02-23 name: Dizal Pharmaceuticals class: INDUSTRY briefSummary: This study tests a combination therapy (i.e., DZD9008 plus bevacizumab) in patients with advanced NSCLC harboring EGFR mutations who have progressed on or after standard of care, which aims to understand whether the combination therapy is safe, how well the combination therapy works, and how the body will process DZD9008 when used in combination with bevacizumab. conditions: Non-small Cell Lung Cancer studyType: INTERVENTIONAL phases: PHASE2 allocation: NA interventionModel: SINGLE_GROUP primaryPurpose: TREATMENT masking: NONE count: 60 type: ESTIMATED name: DZD9008 plus Bevacizumab measure: Part A: 1) Dose Limiting Toxicity (DLT); 2) Treatment-Emergent Adverse Events (TEAEs); TEAEs ≥CTCAE grade 3; and Serious Adverse Events (SAEs). Part B: 1) TEAEs; TEAEs ≥CTCAE grade 3; and SAEs. measure: Part A: 1) Tumor response per RECIST 1.1 and 2) Plasma concentration of DZD9008 and its metabolite. Part B:1) Tumor response per RECIST 1.1; 2) Intracranial tumor response per RECISIT 1.1; 3) Plasma concentration of DZD9008 and its metabolite. sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Shanghai Chest Hospital status: RECRUITING city: Shanghai state: Shanghai zip: 200030 country: China name: Lu, Dr role: CONTACT lat: 31.22222 lon: 121.45806 hasResults: False
nctId: NCT06276270 id: PT-MUC-1_05-21 briefTitle: Multi-centre, Open-label, First-in-man Study With Mucopad HA overallStatus: RECRUITING date: 2023-12-12 date: 2024-12-31 date: 2024-12-31 date: 2024-02-23 date: 2024-02-23 name: Contipro Pharma a.s. class: OTHER briefSummary: The device´s intended use is to treat defects and/or lesions of the oral mucosa, e.g. oral mucositis.To prove safety of the device in terms of clinical results. conditions: Oral Mucositis studyType: INTERVENTIONAL phases: NA allocation: NA interventionModel: SEQUENTIAL primaryPurpose: TREATMENT masking: NONE count: 60 type: ESTIMATED name: Mucopad HA measure: Resolution of mucositis symptoms since completion of radiotherapy measure: - Pain management (VAS scale) measure: Development of xerostomy measure: Subjective evaluation on scale 1-5 of the treatment by investigator/ patient sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Masarykův onkologický ústav, Klinika radiační onkologie status: RECRUITING city: Brno state: Česká Republika zip: 56401 country: Czechia name: Tomáš Novotný role: CONTACT phone: +420543131103 email: novotny@mou.cz lat: 49.19522 lon: 16.60796 facility: FN Hradec Králové Klinika onkologie a radioterapie status: RECRUITING city: Hradec Králové state: Česká Republika zip: 56401 country: Czechia name: Milan Vošmik role: CONTACT phone: +420495832316 email: milan.vosmik@fnhk.cz lat: 50.20923 lon: 15.83277 facility: Fakultní nemocnice Ostrava, Klinika onkologická status: RECRUITING city: Ostrava state: Česká Republika zip: 56401 country: Czechia name: Jana Jackaninová role: CONTACT phone: +420597371111 email: jana.jackaninova@fno.cz lat: 49.83465 lon: 18.28204 facility: Etická komise FN Bulovka status: RECRUITING city: Praha state: Česká Republika zip: 56401 country: Czechia name: Petra Holečková role: CONTACT phone: +420266084516 email: petra.holeckova@bulovka.cz lat: 50.08804 lon: 14.42076 facility: Fakultní Thomayerova nemocnice Onkologická klinika 1.LF UK a FTN status: RECRUITING city: Praha state: Česká Republika zip: 56401 country: Czechia name: Radka Lohynská role: CONTACT phone: +420261083890 email: radka.lohynska@ftn.cz lat: 50.08804 lon: 14.42076 hasResults: False
nctId: NCT06276257 id: 2024-7301 briefTitle: Paravertebral Block for Mastectomy With Immediate Reconstruction overallStatus: NOT_YET_RECRUITING date: 2024-03 date: 2025-07 date: 2025-12 date: 2024-02-23 date: 2024-02-23 name: CHU de Quebec-Universite Laval class: OTHER briefSummary: Following a mastectomy, patients may develop chronic pain, called post-mastectomy pain syndrome (PMPS). This syndrome manifests itself as complex neuropathic pain that seems linked to nerve damage suffered either during surgery, during healing or by nervous system dysfunction. However, the exact pathophysiology remains unknown. Typically, the pain is located on the ipsilateral side of the surgery and projects to the anterior thorax to the lateral thorax and may affect the proximal part of the arm. This pain persists for more than three months following the procedure and has the characteristics of neuropathic pain: burning sensation, tingling, electric shock, hyperalgesia, etc. The prevalence of PMDS varies between 2% and 78%; this disparity comes from the fact that there are no clear criteria in the literature for making the diagnosis. One of the risk factors for developing PMDS is the presence of acute pain immediately postoperatively.
The main objective of this study is to compare two analgesic modalities, namely BPV (study modality) and usual analgesia (control modality), in patients undergoing total mastectomy with immediate reconstruction under general anesthesia with the aim of to evaluate their functional pain score at 24, 48 and 72 hours following the surgical procedure. conditions: Postoperative Pain studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: PREVENTION masking: SINGLE whoMasked: OUTCOMES_ASSESSOR count: 60 type: ESTIMATED name: Paravertebral block name: Usual analgesia measure: Evaluation of postoperative pain using the BPI measure: Total use of opioids received intraoperatively. measure: Use of non-opioid analgesia intraoperatively measure: Total dose of opioids received in the PACU measure: Time before first opioid measure: Total opioids consumed in the 48 hours following surgery measure: Chronic pain sex: FEMALE minimumAge: 18 Years maximumAge: 70 Years stdAges: ADULT stdAges: OLDER_ADULT hasResults: False